DENDREON Corp (DNDN) The FDA’s landmark approval of Dendreon’s prostate cancer vaccine, Provenge, has been warmly welcomed by analysts. After being rejected three years ago, the approval of the drug marks a significant breakthrough for cancer treatment and research. The vaccine, which allows a patient to use their own immune system to fight the disease, [...]